Workshop Purification Therapies – From Research to Clinical Evidence, Milan, Italy, September 30th – October 1st, 2022

Blood Purif 2022;51:2–100

Abstract

The Aferetica team, together with all the partners and collaborators, is very glad to present the scientific contributions of The Workshop Purification Therapies - ‘From Research to Clinical Evidence’, held in Milan the 30th September and the 1st October 2022. This edition of the Workshop is a part of a long Journey, started with the first edition in 2017, or further back in time, with the foundation of Aferetica in 2013, involving an interdisciplinary community of clinicians, researchers and industry partners in an innovation-oriented Collaborative Research cooperation, a concept on the basis and the origins of the greatest medical breakthrough. The transformation of ideas into concrete therapeutical solutions and the establishment of both their widespread application and the clinical evidence in some of the most challenging fields of medicine, Organ Transplantation and Overwhelming inflammatory disorders, were the main topics addressed during the Workshop. The event involved 450 participants from all over Europe to discuss and share experiences about the crucial issues in the field of organ transplantation, with the main focus on the therapeutic solutions for organ ex vivo management, and overwhelming inflammatory disorders diagnosis and purification therapies in order to move forward in their solid clinical applications and more exhaustive knowledge. The scientific contributions included in this Supplement are the result of every-day confrontation and clinical practice. They are divided in categories, according to the major clinical fields and applications, in order to facilitate the comprehension and the comparison of all the presented results. We would like to thank all the members of the Scientific Committee, all the faculty and the participants for bringing their expertise and experience, engaging in such fruitful, constructive and open exchanges throughout the event, allowing to take a step forward in the knowledge of pathologies, therapies, their development and their clinical use.

S. Karger AG, Basel

Article / Publication Details

Received: December 02, 2022
Accepted: December 14, 2022
Published online: February 20, 2023
Issue release date:

Number of Print Pages: 98
Number of Figures: 43
Number of Tables: 0

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Comments (0)

No login
gif